Int. J. Mol. Sci. 2013, 14(5), 10332-10342; doi:10.3390/ijms140510332
Article

Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC

1 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, 47014 Meldola, Italy 2 General Thoracic Surgery, Department of Thoracic Diseases, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy 3 Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, 47014 Meldola, Italy 4 Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, 47014 Meldola, Italy
* Author to whom correspondence should be addressed.
Received: 3 April 2013; in revised form: 2 May 2013 / Accepted: 6 May 2013 / Published: 16 May 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
PDF Full-text Download PDF Full-Text [265 KB, uploaded 16 May 2013 11:34 CEST]
Abstract: Lung cancer is often diagnosed at an advanced stage, with subsequently poor prognosis. There are no biomarkers available to facilitate early diagnosis or to discriminate between benign and malignant nodules. MicroRNAs (miRNAs) are stable molecules that can be found and measured in peripheral blood, thus representing potential diagnostic biomarkers. We evaluated 100 individuals comprising 86 patients with predominantly early-stage non-small cell lung cancer (NSCLC) and 24 healthy donors. RNA was extracted from peripheral blood samples and the expression of a panel of miRNAs was analyzed by Real-Time PCR method. Expression levels of miR-328, miR-18a, miR-339 and miR-140 were significantly higher in NSCLC patients than in healthy donors (p < 0.05). In particular, miR-328 showed good diagnostic accuracy in discriminating between patients with early NSCLC and healthy donors (AUC ROC 0.82, 95% CI 0.72–0.92), with 70% sensitivity and 83% specificity at the best relative expression cut-off of 300. Moreover, miR-339 was a good discriminant between healthy donors and late-stage NSCLC patients (AUC ROC 0.79, 95% CI 0.68–0.91). In conclusion, miR-328 represents a potential diagnostic biomarker of NSCLC, especially for the identification of early-stage tumors. Its role in discriminating between benign and malignant nodules detected by spiral CT warrants further investigation.
Keywords: non small cell lung cancer; miRNAs; diagnosis; serum

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Ulivi, P.; Foschi, G.; Mengozzi, M.; Scarpi, E.; Silvestrini, R.; Amadori, D.; Zoli, W. Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. Int. J. Mol. Sci. 2013, 14, 10332-10342.

AMA Style

Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, Zoli W. Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. International Journal of Molecular Sciences. 2013; 14(5):10332-10342.

Chicago/Turabian Style

Ulivi, Paola; Foschi, Giovanni; Mengozzi, Marta; Scarpi, Emanuela; Silvestrini, Rosella; Amadori, Dino; Zoli, Wainer. 2013. "Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC." Int. J. Mol. Sci. 14, no. 5: 10332-10342.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert